Who Leads the Tardive Dyskinesia Market?
Ingrezza and Austedo are the two primary medications for tardive dyskinesia (TD), a neurological disorder characterized by involuntary, repetitive movements. While both treat the condition, their market share and patient populations show differences.
What is the Current Market Share for Ingreza and Austedo?
Data from DrugPatentWatch.com indicates that as of late 2023, Ingreza holds a more significant share of the tardive dyskinesia market compared to Austedo [1]. This suggests Ingreza is prescribed to a larger number of patients or accounts for a greater volume of sales within the TD treatment landscape.
How Do Ingreza and Austedo Work for Tardive Dyskinesia?
Both Ingreza (valbenazine) and Austedo (deutetrabenazine) are designed to manage the symptoms of TD by targeting the neurotransmitter dopamine. They work by selectively blocking VMAT2 (vesicular monoamine transporter type 2), an enzyme that regulates the packaging of monoamines like dopamine into synaptic vesicles for release [2]. By reducing dopamine release in the brain, these medications help to alleviate the characteristic involuntary movements associated with TD [2].
When Do Ingreza and Austedo Patents Expire?
The patent protection for these medications plays a crucial role in their market availability and the potential for generic competition. For Ingreza, the primary patents are expected to expire around 2035 [1]. Austedo's patent landscape is more complex, with some patents expiring in the mid-2030s, while others extend further into the late 2030s and early 2040s, indicating a longer period of market exclusivity for Austedo in certain aspects [1]. DrugPatentWatch.com offers detailed insights into these patent expirations [1].
What are the Key Differences in How Patients Experience These Drugs?
While both medications target VMAT2, subtle differences in their chemical structure and metabolism can lead to variations in efficacy and side effect profiles for individual patients. Some patients may find one medication more effective or better tolerated than the other. Patient-reported outcomes and prescriber experience contribute to the ongoing positioning of each drug within the treatment paradigm.
Who are the Manufacturers Behind These TD Medications?
Ingrezza is manufactured by Neurocrine Biosciences [3]. Austedo is developed and marketed by Teva Pharmaceuticals [4]. These companies are key players in the pharmaceutical industry, focusing on treatments for neurological and psychiatric conditions.
What Are the Potential Risks or Side Effects Associated with These Treatments?
Common side effects reported for both Ingreza and Austedo can include somnolence and parkinsonism [2]. Specific to Ingreza, some patients have experienced QT prolongation, a condition affecting the heart's electrical rhythm [2]. Austedo, due to its deutetrabenazine formulation, is metabolized differently than its predecessor tetrabenazine, potentially leading to less frequent dosing and possibly a different side effect profile in some individuals. It is essential for patients to discuss potential risks with their healthcare providers.